Live Analyst Rating Changes 18433 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Derek Archila
WF

Derek Archila

Wall Street Analyst
★★★☆☆
#2046
on 13Foresight · ranked by our own returns
48%
Success Rate
+11.3%
Average Return
43 of 89 calls profitable · +5.1% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 48% of Derek Archila's ratings turned a profit when each position was held for 1 year — averaging +11.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

139 Buy 41 Hold 3 Sell
Derek's Stock Coverage 60 ratings · 2026-08-06
Company Date Position Consensus Price Target 1-Yr Return vs S&P 500
ARVN
Arvinas Holding Company
Aug 05, 2026 HOLD Buy
+237.5% avg upside
28 analysts
$11.00
30.89% Upside
+0.0% ·
ORIC
Oric Pharmaceuticals
Aug 04, 2026 BUY Strong Buy
+82.5% avg upside
19 analysts
$25.00
93.45% Upside
+0.0% ·
PYXS
Pyxis Oncology
Aug 03, 2026 BUY Strong Buy
+134.1% avg upside
14 analysts
$12.00
283.36% Upside
· ·
INCY
Incyte
Jul 29, 2026 HOLD Buy
-10.4% avg upside
47 analysts
$116.00
3.25% Downside
-5.7% ·
CLDX
Celldex
Jul 29, 2026 BUY Strong Buy
-0.2% avg upside
28 analysts
$72.00
75.42% Upside
+4.1% ·
TRAX
First Tracks Biotherapeutics Inc
Jul 28, 2026 BUY Strong Buy
+3.1% avg upside
7 analysts
$55.00
17.10% Upside
+14.2% ·
ARGX
Argenx Se
Jul 23, 2026 BUY Strong Buy
-9.9% avg upside
47 analysts
$1350.00
55.55% Upside
-8.7% ·
VRDN
Viridian Therapeutics
Jul 20, 2026 BUY Strong Buy
+68.0% avg upside
32 analysts
$31.00
47.19% Upside
+11.3% ·
RYTM
Rhythm Pharmaceuticals
Jul 16, 2026 BUY Strong Buy
+12.0% avg upside
19 analysts
$155.00
40.03% Upside
-6.5% ·
ANNX
Annexon Biosciences
Jul 15, 2026 BUY Strong Buy
+162.5% avg upside
14 analysts
$27.00
402.80% Upside
-21.6% ·
QTTB
Q32 Bio
Jul 14, 2026 BUY Strong Buy
+265.9% avg upside
24 analysts
$66.00
300.20% Upside
-10.7% ·
NRIX
Nurix Therapeutics
Jul 14, 2026 HOLD Strong Buy
+28.3% avg upside
28 analysts
$25.00
0.55% Downside
+1.0% ·
XFOR
X4 Pharmaceuticals
Jul 10, 2026 BUY Strong Buy
+474.6% avg upside
16 analysts
$11.00
165.04% Upside
-2.7% ·
ALMS
Alumis Inc.
Jul 01, 2026 BUY Strong Buy
+41.3% avg upside
11 analysts
$51.00
88.07% Upside
+1.8% ·
SEPN
Septerna, Inc.
Jun 29, 2026 BUY Strong Buy
+18.0% avg upside
12 analysts
$48.00
23.82% Upside
-1.3% ·
GLUE
Monte Rosa Therapeutics
Jun 24, 2026 BUY Strong Buy
+52.8% avg upside
15 analysts
$29.00
85.82% Upside
-22.3% ·
ASND
Ascendis Pharma
Jun 17, 2026 BUY Strong Buy
+13.0% avg upside
24 analysts
$326.00
33.49% Upside
+5.7% ·
IMVT
Immunovant
May 21, 2026 BUY Strong Buy
-0.4% avg upside
24 analysts
$45.00
14.63% Upside
+13.2% ·
ATYR
aTyr Pharma
May 18, 2026 HOLD Buy
+1521.0% avg upside
17 analysts
$1.00
89.02% Upside
-7.1% ·
CCCC
C4 Therapeutics
May 13, 2026 BUY Strong Buy
+395.4% avg upside
19 analysts
$10.00
176.33% Upside
-1.9% ·
KYTX
Kyverna Therapeutics, Inc.
May 12, 2026 BUY Strong Buy
+257.3% avg upside
7 analysts
$33.00
332.01% Upside
-23.9% ·
BBIO
BridgeBio Pharma
May 09, 2026 BUY Strong Buy
+13.0% avg upside
34 analysts
$98.00
19.53% Upside
+27.5% ·
ALXO
ALX Oncology Holdings
Mar 19, 2026 BUY Strong Buy
+818.9% avg upside
11 analysts
$5.00
160.43% Upside
-10.1% ·
KYMR
Kymera Therapeutics
Mar 02, 2026 BUY Strong Buy
-1.5% avg upside
37 analysts
$116.00
10.03% Upside
+14.8% ·
IRON
Disc Medicine
Mar 02, 2026 BUY Strong Buy
+11.1% avg upside
21 analysts
$79.00
0.08% Upside
+17.1% ·
EXEL
Exelixis
Feb 11, 2026 HOLD Buy
-24.9% avg upside
34 analysts
$35.00
38.20% Downside
+6.8% ·
ALNY
Alnylam Pharma
Jan 20, 2026 HOLD Strong Buy
+43.0% avg upside
51 analysts
$376.00
64.30% Upside
-35.9% ·
ANAB
AnaptysBio
Dec 16, 2025 BUY Strong Buy
+31.7% avg upside
26 analysts
$81.00
47.37% Upside
+83.2% ·
CQP
Cheniere Energy Partners
Dec 16, 2025 SELL Sell
-19.2% avg upside
24 analysts
$56.00
12.69% Downside
-28.8% ·
LQDA
Liquidia Technologies
Oct 17, 2025 BUY Strong Buy
-29.2% avg upside
15 analysts
$31.00
65.22% Downside
+296.7% ·
PTCT
PTC Therapeutics
Oct 17, 2025 BUY Buy
+17.0% avg upside
29 analysts
$73.00
5.47% Upside
+6.8% ·
TECX
Tectonic Therapeutic
Oct 17, 2025 BUY Strong Buy
+91.0% avg upside
24 analysts
$101.00
241.58% Upside
+59.7% ·
STRO
Sutro Biopharma
Aug 12, 2025 HOLD Strong Buy
+53.9% avg upside
20 analysts
$30.00
19.46% Upside
+209.9% ·
CABA
Cabaletta Bio
Aug 08, 2025 HOLD Strong Buy
+410.9% avg upside
16 analysts
$2.00
26.20% Downside
+92.7% ·
ZYME
Zymeworks
Aug 07, 2025 HOLD Strong Buy
+37.4% avg upside
25 analysts
$14.00
40.39% Downside
+80.7% ·
ZNTL
Zentalis Pharmaceuticals
Aug 06, 2025 HOLD Buy
+186.8% avg upside
18 analysts
$5.00
0.93% Upside
+243.5% ·
TSE:WEED
Canopy Growth
Dec 06, 2021 SELL Hold
+1276.8% avg upside
23 analysts
$11.26
765.98% Upside
· ·
SMG
Scotts Miracle-Gro Company
Dec 06, 2021 BUY Strong Buy
+26.7% avg upside
11 analysts
$180.00
172.19% Upside
-60.7% ·
EQ
Equillium
Jun 13, 2021 BUY Strong Buy
+324.4% avg upside
16 analysts
$12.00
447.94% Upside
-66.3% ·
HRTX
Heron Therapeutics
May 13, 2021 BUY Strong Buy
+5274.2% avg upside
21 analysts
$27.00
5248.71% Upside
· ·
URGN
Urogen Pharma
May 13, 2021 BUY Strong Buy
-2.2% avg upside
16 analysts
$30.00
35.48% Downside
-61.3% ·
RNAC
Cartesian Therapeutics
May 13, 2021 HOLD Strong Buy
+279.7% avg upside
19 analysts
$3.00
64.04% Downside
-75.1% ·
LKFT
Lakefront Biotherapeutics
May 09, 2021 HOLD Buy
+304.2% avg upside
24 analysts
$97.00
271.89% Upside
-23.1% ·
MDGL
Madrigal Pharmaceuticals
May 06, 2021 HOLD Strong Buy
-1.9% avg upside
33 analysts
$130.00
74.73% Downside
-49.0% ·
DBVT
DBV Technologies SA - American
May 03, 2021 HOLD Buy
+69.1% avg upside
15 analysts
$6.00
57.96% Downside
-79.3% ·
AMRN
Amarin
Apr 29, 2021 HOLD Buy
-41.4% avg upside
18 analysts
$6.00
58.33% Downside
-48.7% ·
VKTX
Viking Therapeutics
Apr 28, 2021 BUY Strong Buy
+117.0% avg upside
31 analysts
$13.00
61.20% Downside
-62.0% ·
FR:IVA
Inventiva
Mar 05, 2021 BUY Strong Buy
+350.6% avg upside
6 analysts
$16.48
325.23% Upside
-12.4% ·
IVA
Inventiva
Mar 05, 2021 BUY Strong Buy
+240.3% avg upside
17 analysts
$19.00
302.54% Upside
-20.1% ·
GB:0QW0
arGEN X
Mar 04, 2021 HOLD Strong Buy
-16.7% avg upside
24 analysts
$288.82
61.53% Downside
-3.7% ·
NL:LKFT
Galapagos
Feb 19, 2021 HOLD Sell
+129.1% avg upside
16 analysts
$96.00
319.48% Upside
-16.7% ·
FR:GNFT
Genfit
Sep 30, 2020 BUY Strong Buy
+113.5% avg upside
5 analysts
$11.00
21.80% Downside
-14.7% ·
VNDA
Vanda
Jul 10, 2020 HOLD Strong Buy
+300.5% avg upside
13 analysts
+78.6% ·
PCRX
Pacira Pharmaceuticals
Jul 10, 2020 HOLD Buy
+54.3% avg upside
21 analysts
-1.5% ·
ZVRA
Zevra Therapeutics
Apr 02, 2018 BUY Strong Buy
+116.6% avg upside
15 analysts
$13.00
23.47% Upside
-72.9% ·
TRVN
Trevena
Mar 22, 2018 BUY Buy
+1402152.2% avg upside
11 analysts
· ·
PRGO
Perrigo Company
Mar 05, 2018 BUY Buy
+424.0% avg upside
20 analysts
$98.00
638.47% Upside
-39.2% ·
TEVA
Teva Pharmaceutical
Feb 08, 2018 HOLD Buy
-13.6% avg upside
39 analysts
-2.2% ·
TPST
Tempest Therapeutics
Nov 09, 2017 HOLD Buy
+2280.7% avg upside
18 analysts
· ·
VTRS
Viatris
Oct 03, 2017 HOLD Buy
+31.7% avg upside
21 analysts
+12.5% ·
🔒 55 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Derek Archila — Frequently Asked Questions
How accurate are Derek Archila's stock ratings?
Based on the calls 13Foresight could measure, about 49% of Derek's ratings were profitable over a one-year hold, with an average return of +11.4% per rating, or +5.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Derek ranked on 13Foresight?
Derek Archila is currently ranked #2046 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Derek cover?
Derek most recently has ratings on ARVN, ORIC, PYXS, INCY, CLDX, TRAX, ARGX, VRDN, RYTM, ANNX, QTTB, NRIX and 48 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.